1. Lux H, Baur X, Budnik LT, Heutelbeck A, Teixeira JP, Neumann E, et al. Outdoor air pollution from industrial chemicals causing new onset of asthma or COPD: a systematic review protocol. J Occup Med Toxicol. 2020;15(1):1-10.
2. Ramos FL, Krahnke JS, Kim V. Clinical issues of mucus accumulation in COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:139.
3. Khazdair MR, Boskabady MH, Ghorani V. Respiratory effects of sulfur mustard exposure, similarities and differences with asthma and COPD. Inhal Toxicol. 2015;27(14):731-44.
4. Cavaillès A, Brinchault-Rabin G, Dixmier A, Goupil F, Gut-Gobert C, Marchand-Adam S, et al. Comorbidities of COPD. Eur Respir Rev. 2013;22(130):454-75.
5. Banerjee S, Maity P, Mukherjee S, Sil AK, Panda K, Chattopadhyay D, et al. Black tea prevents cigarette smoke-induced apoptosis and lung damage. J Inflam. 2007;4(1):1-12.
6. Goërtz YM, Spruit MA, Van ‘t Hul AJ, Peters JB, Van Herck M, Nakken N, et al. Fatigue is highly prevalent in patients with COPD and correlates poorly with the degree of airflow limitation. Ther Adv Respir Dis. 2019;13.
7. Piras B, Miravitlles M. The overlap phenotype: the (missing) link between asthma and COPD. BioMed Central; 2012.
8. Thornton Snider J, Romley JA, Wong KS, Zhang J, Eber M, Goldman DP. The disability burden of COPD. J Chron Obstruct Pulmon Dis. 2012;9(5):513-21.
9. Voelkel NF, Gomez-Arroyo J, Mizuno S. COPD/emphysema: the vascular story. Pulm Circ. 2011;1(3):320-6.
10. Tajvidi M AM, parsinya M, Babaei Gh. . Effect of training nutrition guide on spirometric indices in patients with COPD. Iran J Nurs Res. 2009;4(15):53-9.
11. Mir Bagheri N MR, Mohammadi A. Effects of regular walking program on quality of life of elderly patients with moderate chronic obstructive pulmonary disease. Iran J Nurs Research. 2008:19-27.
12. Gabriel R, Figueiredo D, Jácome C, Cruz J, Marques A. Day-to-day living with severe chronic obstructive pulmonary disease: towards a family-based approach to the illness impacts. Psychol Health. 2014;29(8):967-83.
13. Cooney A, Mee L, Casey D, Murphy K, Kirwan C, Burke E, et al. Life with chronic obstructive pulmonary disease: striving for ‘controlled co‐existence’. J Clin Nurs. 2013;22(7-8):986-95.
14. Keil DC, Stenzel NM, Kühl K, Vaske I, Mewes R, Rief W, et al. The impact of chronic obstructive pulmonary disease-related fears on disease-specific disability. Chron Respir Dis. 2014;11(1):31-40.
15. Nordén J, Grönberg A, Bosaeus I, Forslund HB, Hulthén L, Rothenberg E, et al. Nutrition impact symptoms and body composition in patients with COPD. Eur J Clin Nutr. 2015;69(2):256-61.
16. Menezes AMB, de Oca MM, Pérez-Padilla R, Nadeau G, Wehrmeister FC, Lopez-Varela MV, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest. 2014;145(2):297-304.
17. Østbye T, Yarnall KS, Krause KM, Pollak KI, Gradison M, Michener JL. Is there time for management of patients with chronic diseases in primary care? Ann Fam Med. 2005;3(3):209-14.
18. Viswanathan M, Golin CE, Jones CD, Ashok M, Blalock SJ, Wines RC, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med. 2012;157(11):785-95.
19. WHO. Chronic obstructive pulmonary disease (COPD). Documentary center of the World Health Organization, 2017.
20. Eisenberg S-L, Eisenberg MJ. Smoking Cessation During the COVID-19 Epidemic. Nicotine Tob Res. 2020;22(9):1664-5.
21. López‐Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14-23.
22. Zyryanov SK, Fitilev SB, Vozzhaev AV, Shkrebniova II, Klyuev DA. Critical aspects of the management of stable coronary artery disease in primary care practice or how to increase the efficacy of evidence-based pharmacological therapy? Res Results Pharmacol. 2020;6:15.
23. Rodriguez-Roisin R, Rabe KF, Vestbo J, Vogelmeier C, Agustí A. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th anniversary: a brief history of time. Eur Respir J. 2017;50(1).
24. Bontsevich R, Gashynova K, Kompaniets O, Batisheva G, Cherenkova O, Shagieva T, et al. Assessment of physicians and undergraduates in COPD: ASCO-2 study. Eur Respir Soc; 2018.
25. Bontsevich RA, Filinichenko TS, Vovk YR, Gavrilova AA, Prozorova GG. Comparative assessment of physicians’ and senior medical students’ basic knowledge in treatment of chronic obstructive pulmonary disease. Res Results Pharmacol. 2019;5(1):67-75.
26. Ter-Levonian AS, Koshechkin KA. Review of Machine Learning Technologies and Neural Networks in Drug Synergy Combination pharmacological research. Res Results Pharmacol. 2020;6:27.
27. Cohen BH, BALL JR WC, Brashears S, Diamond EL, Kreiss P, Levy DA, et al. Risk factors in chronic obstructive pulmonary disease (COPD). Am J Epidemiol. 1977;105(3):223-32.
28. Welte T, Vogelmeier C, Papi A. COPD: early diagnosis and treatment to slow disease progression. Int J Clin Pract. 2015;69(3):336-49.
29. Kulikov OA, Ageev VP, Marochkina EE, Dolgacheva IS, Minayeva OV. Efficacy of liposomal dosage forms and hyperosmolar salines in experimental pharmacotherapy of acute lung injury. Res Results Pharmacol. 2019;5(2):23-41.
30. Siu AL, Bibbins-Domingo K, Grossman DC, Davidson KW, Epling JW, García FA, et al. Screening for chronic obstructive pulmonary disease: US Preventive Services Task Force recommendation statement. Jama. 2016;315(13):1372-7.

31. Gillissen A, Haidl P, Kohlhäufl M, Kroegel K, Voshaar T, Gessner C. The pharmacological treatment of chronic obstructive pulmonary disease. Dtsch Arztebl Int. 2016;113(18):311.
32. Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, et al. The preclinical pharmacology of roflumilast–a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010;23(4):235-56.
33. Murray JF, Nadel J. Textbook of respiratory medicine. 1987.
34. Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019;15:461.
35. Pavord ID, Jones PW, Burgel P-R, Rabe KF. Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:21.
36. Zhukova OV. Monte-Carlo simulation of clinical and economic effectiveness of drugs (on example of antibiotics therapy of acute bronchitis with bronchospasm in children). Res Results Pharmacol. 2019;5:95.
37. Froes F, Roche N, Blasi F. Pneumococcal vaccination and chronic respiratory diseases. Int J Chron Obstruct Pulmon Dis. 2017;12:3457.

38.          Mulpuru S, Li L, Ye L, Hatchette T, Andrew M, Ambrose A, et al. Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN) Effectiveness of influenza vaccination on hospitalizations and risk factors for severe outcomes in hospitalized patients with COPD. Chest. 2019;155(1):69-78.